These data suggest that inhibition of NF-κB signaling is an effective therapy for PARP inhibitor-resistant cancers, and that inhibition of NF-κB signaling reverses cellular sensitivity to PARP inhibition in resistant cells. The gene discussed is PARP1; the disease is cancer.